<DOC>
	<DOCNO>NCT01332305</DOCNO>
	<brief_summary>The objective study generate data necessary determine gabapentin exposure produce 4 dose level GEn ( 600 mg , 1200 mg , 1800 mg , 2400 mg ) placebo , correspond relief symptom subject Restless Legs Syndrome ( RLS ) .</brief_summary>
	<brief_title>Dose-Response Pharmacokinetics Gabapentin Enacarbil ( GEn XP13512 / GSK1838262 ) Restless Legs Syndrome</brief_title>
	<detailed_description>This multicenter , randomize , double blind , placebo control , parallel group study , compare 4 dos GEn ( XP13512 ) placebo give daily subject RLS . Eligible subject randomize equal number 1 5 treatment group ( GEn 600 mg , 1200 mg , 1800 mg , 2400 mg placebo ) 12 week treatment . Data study utilized part large pharmacokinetic ( PK ) pharmacodynamic ( PD ) analysis data several study ( XP084/RXP111495 ) part GEn RLS clinical development program . Safety tolerability also assess .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Psychomotor Agitation</mesh_term>
	<mesh_term>Restless Legs Syndrome</mesh_term>
	<criteria>Men woman least 18 year age RLS , base IRLSSG Diagnostic Criteria History RLS symptom occur least 15 night month prior Screening , RLS treatment , frequency symptom must applicable prior start treatment Documented RLS symptoms least 4 7 consecutive evenings/nights Total RLS severity score 15 great IRLS Rating Scale If take dopamine agonist , gabapentin , treatment RLS ( e.g. , opioids , benzodiazepine ) medication must discontinue least 2 week prior Screening ; If take prescription medication , therapy must stabilize least 3 month prior Screening anticipate change duration study ; Body Mass Index ( BMI ) 34 estimate creatinine clearance least 60 mL/min sleep disorder ( e.g. , sleep apnea ) may significantly affect assessment RLS history RLS symptom augmentation end dose rebound previous dopamine agonist treatment neurologic disease movement disorder ( e.g. , diabetic neuropathy , Parkinson 's disease , multiple sclerosis , dyskinesia , dystonias ) ; clinically significant unstable medical condition condition could affect RLS treatment efficacy assessment serum ferritin level 20 ng/mL currently suffer moderate severe depression use Diagnostic Statistical Manual Mental Disorders Treatment IV ( DSM IV TR )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2011</verification_date>
</DOC>